The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Shoemaker Daniel D since 2014.
This trader's CIK number is 1586892.
At the time of last reporting, Shoemaker Daniel D was the Chief Scientific Officer of Fate Therapeutics Inc. (stock ticker symbol FATE).
Also see all insider trading activities at Fate Therapeutics Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | FATE | 0 | $0 | 34,482 | $3,148,354 | 0 | $0 |
| 2020 | FATE | 0 | $0 | 80,700 | $2,807,559 | 25,000 | $72,500 |
| 2019 | FATE | 0 | $0 | 36,800 | $632,910 | 25,000 | $72,500 |
| 2017 | FATE | 0 | $0 | 13,225 | $51,202 | 0 | $0 |
| 2014 | FATE | 0 | $0 | 8,653 | $88,260 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-03-08 | FATE | Sale | 25,000 | 82.55 | 2,063,725 |
| 2021-01-08 | FATE | Sale | 6,229 | 116.33 | 724,600 |
| 2021-01-11 | FATE | Sale | 3,253 | 110.68 | 360,029 |
| 2020-11-16 | FATE | Sale | 25,000 | 51.46 | 1,286,400 |
| 2020-09-14 | FATE | Sale | 25,000 | 36.21 | 905,250 |
| 2020-01-08 | FATE | Sale | 5,700 | 20.70 | 117,984 |
| 2019-12-30 | FATE | Option Ex | 25,000 | 2.90 | 72,500 |
| 2019-12-30 | FATE | Sale | 25,000 | 19.92 | 497,925 |
| 2019-10-15 | FATE | Sale | 11,800 | 14.29 | 168,598 |
| 2019-06-27 | FATE | Sale | 12,500 | 20.21 | 252,612 |
| 2019-06-27 | FATE | Option Ex | 12,500 | 2.90 | 36,250 |
| 2019-03-28 | FATE | Option Ex | 12,500 | 2.90 | 36,250 |
| 2019-03-28 | FATE | Sale | 12,500 | 16.94 | 211,700 |
| 2017-10-13 | FATE | Sale | 12,525 | 3.86 | 48,346 |
| 2017-10-16 | FATE | Sale | 700 | 4.08 | 2,856 |
| 2014-03-31 | FATE | Sale | 8,653 | 10.20 | 88,260 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Shoemaker Daniel D (Chief Scientific Officer of Fate Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.